Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, CSR, ESG

BIO-TECHNE ISSUES 2024 CORPORATE SUSTAINABILITY REPORT


MINNEAPOLIS, Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate culture and provide the foundation for our approach to continuously improving our corporate sustainability. The updated CSR is available in the Corporate and Social Responsibility section of Bio-Techne's website.

"I am proud of the progress the team continues to make positioning Bio-Techne for a sustainable future," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our global team remains committed to enriching the communities we live and work in, while delivering the innovation the scientific community relies on to catalyze advances in science and medicine. These are achieved while functioning at the highest level of governance and operational integrity. This focus enables the team to grow the organization in a responsible manner and deliver the products necessary to develop and advance the next generation of therapeutics, vaccines and diagnostics that improve global healthcare."

"This latest CSR includes several noteworthy advancements in our sustainability journey," commented Shane Bohnen, Chief Sustainability Officer, General Counsel and Corporate Secretary. "Specifically, we submitted a letter of commitment to reduce our Scope 1, 2 and 3 greenhouse gas emissions, and our reduction targets will be evaluated by the Science Based Targets Initiative (SBTI) in 2026. We also completed our first EcoVadis sustainability assessment to evaluate our performance in environment, labor and human rights, ethics and sustainable procurement, and earned a Bronze Medal in this inaugural evaluation, putting us in the top 67% of all companies assessed. I am looking forward to sharing the team's continued progress furthering our sustainability initiatives."

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations
[email protected] 
612-656-441

BT Logo (PRNewsfoto/Bio-Techne Corporation)

SOURCE Bio-Techne Corporation


These press releases may also interest you

at 14:02
Kratom Extract Market is Segmented by Type (Liquid, Powder, Capsules, Gummies), by Application (Offline, Online). The Kratom Extract...

at 14:00
Early-life exposure to antibiotics can be a risk factor for childhood asthma, according to new research being presented at the 2025 AAAAI / WAO Joint Congress in San Diego, CA, later this month. "postnatal antibiotic therapy for maternal...

at 14:00
Phoenix Children's, one of the nation's largest and fastest-growing pediatric healthcare systems, today announced the retirement of Robert L. Meyer, who has served as the organization's President and CEO for 22 years. Working closely with the Board...

at 13:57
Nearly two-thirds of America's dogs and cats are overweight or obese1, putting them at increased risk for serious health problems like diabetes, heart disease, and joint issues. To combat this growing crisis, Hill's Pet Nutrition, a global leader in...

at 13:46
This inspiring book offers 366 days of guided reflections,...

at 13:35
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolyssetm Form and Evolyssetm Smooth injectable hyaluronic acid (HA) gels, the...



News published on and distributed by: